Bantam Pharmaceutical (United States)

Bantam Pharmaceutical is a private biotechnology company based in Research Triangle Park, North Carolina, USA. It is developing novel, first-in-class oral small molecule therapeutics for difficult-to-treat hematological and solid tumors. The company's lead candidate is BTM-3566, an orally available small molecule initially focused on lymphomas such as DLBCL, MCL, and FL. Founded in 2015, the company pivoted to mitochondrial dynamics in 2017 and identified BTM-3566 in 2019.

Bantam Pharmaceutical was founded in 2015 based on acquired Harvard IP. In 2017, the company switched focus to mitochondrial dynamics. In 2019, BTM-3566 was identified as the first clinical candidate with an initial focus in lymphoma. In 2020, a CMC campaign and initiation of IND enabling studies occurred. From 2021-2022, the company moved to IND with Ph 1a/1b evidence of clinical efficacy. In 2025, the company initiated its first clinical trial for BTM-3566.

• BTM-3566

  Orally-available novel small molecule compound with broad anti-cancer activity in hematologic and solid tumors, initially focused on Diffuse Large B-cell Lymphoma (DLBCL).

• 2021.04.28

  Reported2021.04.28

  Bantam Pharmaceutical names Michael Stocum CEO[4]Bantam Pharmaceutical任命Michael Stocum为首席执行官prnewswire.com

  Bantam Pharmaceutical announced that it had named Michael Stocum president and chief executive officer, succeeding founding CEO Mike Luther.

Read more

1. 1Bantam Pharma | Redefining Cancer Carebantampharma.com
2. 2About Us | Bantam Pharmabantampharma.com
3. 3Bantam Pharmaceutical (United States)wikidata.org
4. 4Bantam Pharmaceutical任命Michael Stocum为首席执行官prnewswire.com